AAO Updates HCQ Retinopathy Guidance - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

AAO Updates HCQ Retinopathy Guidance

Updated recommendations emphasize dosing limits and screening for toxicity risk.

  • By

  • Andrea Surnit

  • April 23, 2026

  • 3 min

Share

Objective:

To update screening recommendations for hydroxychloroquine (HCQ) retinopathy based on recent advances in retinal imaging and artificial intelligence.

Approach:
    Key Findings:
    • Risk of HCQ retinopathy is less than 1% within 5 years and less than 2% within 10 years at doses up to 5 mg/kg/day.
    • Annual risk remains below 5% after 20 years for patients without prior toxicity.
    • Risk of toxicity increases with higher doses, longer durations, renal disease, and older age at treatment initiation.
    Interpretation:

    With proper dosing and annual screening, most patients can safely use HCQ for extended periods with a low risk of retinal toxicity.

    Limitations:
    • Risk estimates depend on adherence to dosing and screening.
    • Newer AI-based imaging technologies are not yet fully validated for routine clinical use.
    Conclusion:

    Baseline screening is recommended at treatment initiation, with annual follow-ups, although screening may be deferred for low-risk patients.

    Sources:

Original Source(s)

AAO Updates HCQ Retinopathy Guidance

  • by Andrea Surnit

  • April 23, 2026

Related Content

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

Blindness Linked to Higher Loneliness Scores

Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.

Glycemic variability may signal retinal changes

Greater glucose fluctuations but not HbA1c were associated with neuroretinal alterations over 3 years in pediatric patients with type 1 diabetes.